Linda Rubinstein

Linda M.
Rubinstein is Chief Financial & Accounting Officer at Nektar Therapeutics since 2026.
Ms. Rubinstein is Partner at FLG Partners LLC since 2010.
Former roles include Independent Director at Biocept, Inc. from 2021 to 2023; Chief Accounting Officer at Alector, Inc. in 2022; Chief Financial & Accounting Officer at Adverum Biotechnologies, Inc. from 2022 to 2025; Chief Financial Officer at Apexigen, Inc. from 2018 to 2022; Chief Financial & Accounting Officer at Five Prime Therapeutics, Inc. in 2018; Chief Financial Officer at ArmaGen, Inc. from 2015 to 2020; Chief Financial Officer & Executive Vice President at Emergent Travel Health, Inc. in 2014; Director at Sensor Innovations, Inc. from 2007 to 2015; Chief Financial Officer at Solexa, Inc. from 2005 to 2007; Chief Financial Officer & Senior Vice President at Ingenuity Systems, Inc.; Chief Financial Officer at RenovoRx, Inc.; Chief Financial Officer at iPierian, Inc.; Senior Banker at Lehman Brothers, Inc.; Principal at Merrill Lynch Capital Partners, Inc.; and Chief Financial Officer at iPierian, Inc. Education includes undergraduate and graduate degrees from the University of California, Los Angeles.